Abstract
For the last two decades, there has been research interest on the design of molecules possessing dual inhibitory potential on cholinesterase and monoamine oxidase enzymes, particularly for the treatment of two major neurodegenerative diseases, Alzheimer’s Disease (AD) and Parkinson’s disease (PD). Many compounds have been synthesized for this purpose, and some of them have been shown to display activities comparable or superior to the activities of current drugs used for the treatment of AD and PD. Within the concept of this review study, we have aimed to present the current drugs used for the treatment of AD and PD, their mechanism of action, the discussion behind the theory of designing dual inhibitor agents, and the presentation of the most active compounds with diverse heterocyclic scaffolds displayed in research studies published in the recent period.
Keywords: Alzheimer's disease, Parkinson’s disease, Dual inhibitors, Monoamine oxidase, Cholinesterase, Heterocyclic scaffolds.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds
Volume: 21 Issue: 30
Author(s): Hayrettin O. Gulcan*Ilkay E. Orhan*
Affiliation:
- Faculty of Pharmacy, Eastern Mediterranean University, Famagusta, T.R. North Cyprus, via Mersin 10,Turkey
- Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330, Ankara,Turkey
Keywords: Alzheimer's disease, Parkinson’s disease, Dual inhibitors, Monoamine oxidase, Cholinesterase, Heterocyclic scaffolds.
Abstract: For the last two decades, there has been research interest on the design of molecules possessing dual inhibitory potential on cholinesterase and monoamine oxidase enzymes, particularly for the treatment of two major neurodegenerative diseases, Alzheimer’s Disease (AD) and Parkinson’s disease (PD). Many compounds have been synthesized for this purpose, and some of them have been shown to display activities comparable or superior to the activities of current drugs used for the treatment of AD and PD. Within the concept of this review study, we have aimed to present the current drugs used for the treatment of AD and PD, their mechanism of action, the discussion behind the theory of designing dual inhibitor agents, and the presentation of the most active compounds with diverse heterocyclic scaffolds displayed in research studies published in the recent period.
Export Options
About this article
Cite this article as:
Gulcan O. Hayrettin *, Orhan E. Ilkay *, Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds, Current Topics in Medicinal Chemistry 2021; 21 (30) . https://dx.doi.org/10.2174/1568026621666210902121148
DOI https://dx.doi.org/10.2174/1568026621666210902121148 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
Current Pharmaceutical Design On the Diversity of Oxidative Bioactivation Reactions on Nitrogen- Containing Xenobiotics
Current Drug Metabolism Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Mitochondria as an Easy Target to Oxidative Stress Events in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design New Avenue of Research: Antiepileptic Drug and Estradiol Neuroprotection in Epilepsy
Recent Patents on CNS Drug Discovery (Discontinued) Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry New Therapeutic Strategy for Parkinson’s and Alzheimer’s Disease
Current Medicinal Chemistry Neurodegeneration and the Heat Shock Protein 70 Machinery: Implications for Therapeutic Development
Current Topics in Medicinal Chemistry Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry Ethnobotanical Treatment Strategies Against Alzheimers Disease
Current Alzheimer Research Therapeutic Role of Zonisamide in Neuropsychiatric Disorders
Mini-Reviews in Medicinal Chemistry Cerebrospinal-fluid Alzheimer’s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets Biochemical and Therapeutic Effects of Antioxidants in the Treatment of Alzheimers Disease, Parkinsons Disease, and Amyotrophic Lateral Sclerosis
Current Drug Targets - CNS & Neurological Disorders Overview of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets